Avid Bioservices, Inc.
CDMO · NASDAQ
10/31/2024 | 7/31/2024 | 4/30/2024 | 1/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.31 | -0.00 | 0.49 |
| FCF Yield | 1.63% | -0.75% | -0.92% | -0.19% |
| EV / EBITDA | -79.54 | -3,275.17 | -1,166.14 | -182.52 |
| Quality | ||||
| ROIC | -5.01% | -0.92% | -0.48% | -0.91% |
| Gross Margin | -6.11% | 14.22% | 12.80% | 7.05% |
| Cash Conversion Ratio | 0.19 | 0.66 | -0.01 | -0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.89% | 4.28% | 5.37% | 5.64% |
| Free Cash Flow Growth | 308.07% | -12.51% | -453.81% | 34.56% |
| Safety | ||||
| Net Debt / EBITDA | -16.94 | -679.89 | -302.55 | -50.87 |
| Interest Coverage | -3.86 | -1.00 | -0.71 | -4.57 |
| Efficiency | ||||
| Inventory Turnover | 1.27 | 1.18 | 1.23 | 0.91 |
| Cash Conversion Cycle | 128.90 | 102.81 | 84.06 | 124.91 |